Evidence map›Paper›PMID 38912329›Full record

ArticleLancet regional health. Americas2024

Impact of Xpert MTB/RIF implementation in tuberculosis case detection and control in Brazil: a nationwide intervention time-series analysis (2011-2022).

Klauss Villalva-Serra, Beatriz Barreto-Duarte, João P Miguez-Pinto, Artur T L Queiroz, Moreno M Rodrigues, Peter F Rebeiro, Gustavo Amorim, Marcelo Cordeiro-Santos, Timothy R Sterling, Mariana Araújo-Pereira and 1 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Temporal Trends in Tuberculosis Incidence in the 1st Health Region of Alagoas, Brazil (2001-2022).International journal of environmental research and public health · 2025
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Klauss Villalva-SerraCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
Beatriz Barreto-DuarteCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
João P Miguez-PintoCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.
Artur T L QueirozMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Moreno M RodriguesMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Peter F RebeiroDivision of Infectious Diseases & Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Gustavo AmorimDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, TN, USA.
Marcelo Cordeiro-SantosFundação Medicina Tropical Dr Heitor Vieira Dourado, Manaus, Brazil.
Timothy R SterlingDivision of Infectious Diseases & Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.
Mariana Araújo-PereiraMultinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Brazil.
Bruno B AndradeCurso de Medicina, Universidade Salvador (UNIFACS), Salvador, Brazil.

Funding

Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil NetworkU01AI172064 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BRUNO DE BEZERRIL ANDRADE, TIMOTHY R STERLING · 2023 to 2026
$4.0M
NIAID NIH HHS U01 AI172064
6 · The paper itself

Abstract

Background: Since 2014, Brazil has gradually implemented the Xpert MTB/RIF (Xpert) test to enhance early tuberculosis (TB) and drug-resistant (DR-TB) detection and control, yet its nationwide impact remains underexplored. Our study conducts an intervention time-series analysis (ITSA) to evaluate how the Xpert's implementation has improved TB and DR-TB detection nationwide. Methods: 1,061,776 cases from Brazil's National TB Registry (2011-2022) were reviewed and ITSA (2011-2019) was used to gauge the impact of the Xpert's adoption on TB and DR-TB notification. Granger Causality and dynamic regression modelling determined if incorporating Xpert testing as an external regressor enhanced forecasting accuracy for Brazil's future TB trends. Findings: Xpert implementation resulted in a 9.7% increase in TB notification and substantial improvements in DR-TB (63.6%) and drug-susceptible TB (92.1%) detection compared to expected notifications if it had not been implemented. Xpert testing counts also presented a time-dependent relationship with DR-TB detection post-implementation, and improved predictions in forecasting models, which depicted a potential increase in TB and DR-TB detection in the next six years. Interpretation: This study underscores the critical role of Xpert's adoption in boosting TB and DR-TB detection in Brazil, reinforcing the case for its widespread use in disease control. Improvements in prediction accuracy resulting from integrating Xpert data are crucial for allocating resources and reducing the incidence of TB. By acknowledging Xpert's role in both disease control and improving predictions, we advocate for its expanded use and further research into advanced molecular diagnostics for effective TB and DR-TB control. Funding: FIOCRUZ.

Indexed as

BrazilDrug-resistant tuberculosisIntervention time-seriesLaboratory diagnosticsPublic health measuresXpert MTB/RIF

Identifiers

PMID38912329
PMCPMC11192787

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.